Sintaho Pharmaceutical Ltd was established in the year of 2016 and headquartered in Chongqing China, with a grand vison of being the most trusted partner to pharmaceutical companies worldwide. We have a clear focus on developing and manufacturing highly potent and cytotoxic Active Pharmaceutical Ingredients (APIs) and CDMO services.
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Olaparib is a potent <strong>PARP inhibitor</strong> used in oncology. Its synthesis involves advanced organic chemistry with high purity standards. Molecular formula: C<sub>24</sub>H<sub>26</sub>N<sub>6</sub>O<sub>5</sub>. CAS No.: 763113-22-0.</p>
<h3>Application</h3>
<ul>
<li><strong>Oncology Manufacturing:</strong> Production of pharmaceutical grade API for BRCA-mutated cancers.</li>
<li><strong>Research & Development:</strong> Used in clinical trials for synthetic lethality studies.</li>
<li><strong>Distribution:</strong> Supply to global CDMOs and hospital pharmacies.</li>
</ul>
<h3>Precautions</h3>
<p>Requires strict temperature control (2-8°C) during storage. Handling mandates PPE due to potential mutagenicity. Clinical use is restricted to patients with specific genetic markers under physician supervision.</p>